


- 
- February 2020** Our research findings based on artificial intelligence (AI) were published twice in the Lancet journals
- March** Doctors in Italy commence independent trials, followed by Spain
- April** Scientists at Lilly independently validate the anti-cytokine and anti-viral hypotheses
- May** NIAID and Lilly commence large ACTT-II randomised trial
- May** EMBO Molecular Medicine publish our initial patient experience and detailed scientific data validating the original AI hypothesis
- June** Lilly commence large scale randomised placebo-controlled global trial, COV-BARRIER
- September** Journal of Allergy and Clinical Immunology publishes our cytokine changes in mild to severe COVID-19 and healthy controls showing baricitinib suppresses the storm
- September** ACTT-II randomised trial hits pre-specified primary endpoint in >1000 patients hospitalised with COVID-19
- October** The Journal of the National Cancer Institute publishes our meta-analysis of cancer and COVID-19 showing a 22.4% mortality
- November 13th** Science Advances publishes our paper, Stebbing *et al.*, with over 50 authors, 30 institutions around the world, linking the computer to the laboratory to the clinic including the first elderly cohort with COVID-19 pneumonia (median age 81)
- November 19th** FDA grants Emergency Use Authorisation for baricitinib in COVID-19